Trial reportThe Journal of allergy and clinical immunology2007
Nonlinear pharmacokinetics of high-dose recombinant fusion protein CD4-IgG2 (PRO 542) observed in HIV-1-infected children.
Trial report in The Journal of allergy and clinical immunology, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00253695 (Sleep Studies in HIV+ Older Children/Adolescents), which is not on this map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Sleep Studies in HIV+ Older Children/Adolescents
Who cites it
13 citing papers in PubMed, 26 citations in OpenAlex.
- In vivo affinity maturation of the CD4 domains of an HIV-1-entry inhibitor.Nature biomedical engineering · 2024Article
- Article
- Designed variants of ACE2-Fc that decouple anti-SARS-CoV-2 activities from unwanted cardiovascular effects.International journal of biological macromolecules · 2020Article
- HIV Entry and Its Inhibition by Bifunctional Antiviral Proteins.Molecular therapy. Nucleic acids · 2018Review
- Further Characterization of the Bifunctional HIV Entry Inhibitor sCD4-FIMolecular therapy. Nucleic acids · 2017Article
- A Little Help From the Follicles: Understanding the Germinal Center Response to Human Immunodeficiency Virus 1 Infection and Prophylactic Vaccines.Clinical medicine insights. Pathology · 2017Review
- Driving HIV-1 into a Vulnerable Corner by Taking Advantage of Viral Adaptation and Evolution.Frontiers in microbiology · 2017Review
- Engineering broadly neutralizing antibodies for HIV prevention and therapy.Advanced drug delivery reviews · 2016Review
- Anti-infective immunoadhesins from plants.Plant biotechnology journal · 2015Review
- Article
- Exceptionally potent and broadly cross-reactive, bispecific multivalent HIV-1 inhibitors based on single human CD4 and antibody domains.Journal of virology · 2014Article
- Engineered single human CD4 domains as potent HIV-1 inhibitors and components of vaccine immunogens.Journal of virology · 2011Article
- Molecular decoys: antidotes, therapeutics and immunomodulators.Current opinion in biotechnology · 2008Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 11 institutions in 2 countries.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.